Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Single-Center Study of Cyporin N 0.05% Eye Drops in Dry Eye Patients with Meibomian Gland Dysfunction
KCT0004199Phase 4Completed
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Aug 2019
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of TJO-087 in dry eye syndrome (DED), meibomian gland dysfunction (MGD), sponsored by Taejoon Pharmaceutical Co., Ltd.. Started Aug 2019; status: completed.
02
Drugs
TJO-087
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on KCT0004199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004199.